Journals
Publish with us
Publishing partnerships
About us
Blog
BioMed Research International
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
BioMed Research International
/
2015
/
Article
/
Tab 4
/
Review Article
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting
Table 4
Efficacy of NEPA in gender/age emetic risk groups.
Overall (0–120 h) CR
% of patients
NEPA + DEX
Oral PALO + DEX
% Difference (95% CI)
Females <55 years
(high risk)
(
)
80.0
69.0
11.0 (−1.0; 23.0)
Females ≥55 years
(moderate risk)
(
)
84.5
69.4
15.0 (3.9; 26.2)
Males <55 years
(low risk)
(
)
89.7
71.4
18.3 (7.6; 29.0)
Males ≥55 years
(lowest risk)
(
)
92.8
81.1
11.7 (5.0; 18.5)
NEPA: netupitant/palonosetron; PALO: palonosetron; CR: complete response; CI: confidence interval.